🇺🇸 FDA
Pipeline program

VX-840

VX21-840-001

Phase 1 small_molecule completed

Quick answer

VX-840 for APOL1-mediated Kidney Disease is a Phase 1 program (small_molecule) at VERTEX PHARMACEUTICALS INC / MA with 1 ClinicalTrials.gov record(s).

Program details

Company
VERTEX PHARMACEUTICALS INC / MA
Indication
APOL1-mediated Kidney Disease
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials